Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

Exosome Diagnostics and Leading Academic Cancer Center Demonstrate Superior Liquid Biopsy Performance

November 13, 2017 - Waltham, MA - Exosome Diagnostics, Inc., and MD Anderson Cancer Center had a unique study published in Clinical Cancer Research, a peer reviewed publication of the American Association of Clinical Cancer Research. The analysis directly compared Exosome Diagnostics’ ExoLution® Plus platform with two different platforms, BEAMing and ddPCR, analysing cfDNA alone. Teams at MD Anderson Cancer Center and Exosome Diagnostics showed that the ExoLution Plus platform, which simultaneously analyses exoNA and cfDNA correlated better to clinical outcome than cfDNA analysis alone in a cohort of 43 patients with progressive advanced cancer. The teams studied overall survival among the patients and linked low amounts of mutated exosome nucleic acids (exoNA) with longer survival times and high amounts of mutated exoNA with shorter survival times.

"Our study reports two novel observations. First, our data suggest that next-generation sequencing of plasma-derived exosomal nucleic acids from patients with advanced cancers has high sensitivity compared to molecular testing of plasma cell-free DNA or archival tumor samples. Second, we demonstrated that the amount of mutated exosomal nucleic acids is an independent prognostic factor for survival" said Filip Janku, senior author on the study (MD Anderson Cancer Center.)

“Exosomal nucleic acid performed better than cfDNA irrespective if the cfDNA analysis was done using sensitive platforms such as ddPCR and BEAMing, possibly due to the fact that exosomes originates from living cancer cells vs cfDNA from dead cancer cells”, said Johan Skog, Chief Scientific Officer at Exosome Diagnostics.

“This publication is further validation of the ExoDx’s proprietary platform superiority to cfDNA platforms.” Stated, John Boyce, President and CEO. “Our team has spent the last several years doing direct comparisons of ExoLution Plus to competitive cfDNA and other exosome RNA isolation platforms and have always demonstrated the superior performance of the ExoDx platform whether it is outcome correlation, superior mutation detection, or quantity / quality of RNA found,” Boyce continued. “This strengthens our leadership position in the liquid biopsy space with technology that will translate to superior diagnostic tests for better healthcare.”

Download a PDF of this press release

About Clinical Cancer Research

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, ShahkyTM, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.

Media Contact

Dan Baughman
dbaughman@exosomedx.com
phone: 248 613 2247